Across the recent three months, 8 analysts have shared their insights on Cigna Group CI, expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 4 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 1 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 2 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $348.25, a high estimate of $372.00, and a low estimate of $327.00. Observing a 0.36% increase, the current average has risen from the previous average price target of $347.00.
Diving into Analyst Ratings: An In-Depth Exploration
An in-depth analysis of recent analyst actions unveils how financial experts perceive Cigna Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| George Hill | Deutsche Bank | Raises | Buy | $370.00 | $355.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Neutral | $334.00 | - |
| Michael Wiederhorn | Oppenheimer | Maintains | Outperform | $360.00 | - |
| Lance Wilkes | Bernstein | Announces | Outperform | $372.00 | - |
| George Hill | Deutsche Bank | Raises | Hold | $355.00 | $351.00 |
| David Windley | Jefferies | Raises | Buy | $341.00 | $335.00 |
| Ben Hendrix | RBC Capital | Maintains | Sector Perform | $327.00 | - |
| Ben Hendrix | RBC Capital | Maintains | Sector Perform | $327.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cigna Group. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cigna Group compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Cigna Group's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Cigna Group's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Cigna Group analyst ratings.
About Cigna Group
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 18 million U.S. medical members covered as of the end of June 2023.
Cigna Group's Economic Impact: An Analysis
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Cigna Group displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 8.46%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Cigna Group's net margin is impressive, surpassing industry averages. With a net margin of 2.87%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Cigna Group's ROE stands out, surpassing industry averages. With an impressive ROE of 3.09%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Cigna Group's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.94% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Cigna Group's debt-to-equity ratio is below the industry average at 0.68, reflecting a lower dependency on debt financing and a more conservative financial approach.
What Are Analyst Ratings?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
